Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Fletcher and Christopher Fletcher.
Connection Strength

3.009
  1. Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest? Appl Immunohistochem Mol Morphol. 2002 Sep; 10(3):197-8.
    View in: PubMed
    Score: 0.265
  2. Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest? Am J Clin Pathol. 2002 Aug; 118(2):163-4.
    View in: PubMed
    Score: 0.264
  3. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.149
  4. Gastrointestinal stromal tumors. Virchows Arch. 2010 Feb; 456(2):111-27.
    View in: PubMed
    Score: 0.111
  5. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009 Jul; 218(3):292-300.
    View in: PubMed
    Score: 0.106
  6. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20; 26(33):5360-7.
    View in: PubMed
    Score: 0.102
  7. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep; 216(1):64-74.
    View in: PubMed
    Score: 0.101
  8. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene. 2008 Sep 18; 27(42):5624-34.
    View in: PubMed
    Score: 0.099
  9. Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol. 2007 May; 31(5):737-43.
    View in: PubMed
    Score: 0.092
  10. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene. 2007 Sep 27; 26(44):6386-95.
    View in: PubMed
    Score: 0.091
  11. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10; 24(29):4764-74.
    View in: PubMed
    Score: 0.088
  12. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004 Aug 01; 64(15):5127-31.
    View in: PubMed
    Score: 0.076
  13. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004 Jul; 28(7):889-94.
    View in: PubMed
    Score: 0.075
  14. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004 May 13; 23(22):3999-4006.
    View in: PubMed
    Score: 0.075
  15. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004; 22(1):106-16.
    View in: PubMed
    Score: 0.073
  16. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
    View in: PubMed
    Score: 0.072
  17. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607):708-10.
    View in: PubMed
    Score: 0.068
  18. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002 Sep 15; 20(18):3898-905.
    View in: PubMed
    Score: 0.066
  19. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? Am J Pathol. 2002 Aug; 161(2):737-8; author reply 738-9.
    View in: PubMed
    Score: 0.066
  20. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15; 61(22):8118-21.
    View in: PubMed
    Score: 0.063
  21. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? Histopathology. 2001 Jul; 39(1):100-3.
    View in: PubMed
    Score: 0.061
  22. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod pathol 2000;13:1336-46. Mod Pathol. 2001 Jul; 14(7):733-7.
    View in: PubMed
    Score: 0.061
  23. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000 Aug; 157(2):377-84.
    View in: PubMed
    Score: 0.057
  24. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol. 2021 01; 34(1):95-103.
    View in: PubMed
    Score: 0.057
  25. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000 Mar; 156(3):791-5.
    View in: PubMed
    Score: 0.056
  26. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol. 2000 Jan; 8(1):5-10.
    View in: PubMed
    Score: 0.055
  27. Spindle cell rhabdomyosarcoma (so-called) in adults: report of two cases with emphasis on differential diagnosis. Am J Surg Pathol. 1998 Apr; 22(4):459-64.
    View in: PubMed
    Score: 0.049
  28. Primary cutaneous Ewing's sarcoma: immunophenotypic and molecular cytogenetic evaluation of five cases. Am J Surg Pathol. 1998 Mar; 22(3):310-8.
    View in: PubMed
    Score: 0.049
  29. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 Oct; 234(2):190-202.
    View in: PubMed
    Score: 0.038
  30. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.031
  31. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 2010 Jan; 220(1):58-70.
    View in: PubMed
    Score: 0.028
  32. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
    View in: PubMed
    Score: 0.027
  33. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20; 26(33):5352-9.
    View in: PubMed
    Score: 0.025
  34. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01; 26(4):620-5.
    View in: PubMed
    Score: 0.024
  35. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
    View in: PubMed
    Score: 0.024
  36. Insulin receptor activation in solitary fibrous tumours. J Pathol. 2007 Apr; 211(5):550-554.
    View in: PubMed
    Score: 0.023
  37. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9502.
    View in: PubMed
    Score: 0.022
  38. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9011.
    View in: PubMed
    Score: 0.020
  39. Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005 Jun; 23(16_suppl):9010.
    View in: PubMed
    Score: 0.020
  40. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
    View in: PubMed
    Score: 0.019
  41. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
    View in: PubMed
    Score: 0.019
  42. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer. 2004 Jul; 40(3):218-28.
    View in: PubMed
    Score: 0.019
  43. Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol. 2004 May; 164(5):1645-53.
    View in: PubMed
    Score: 0.019
  44. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun; 9(6):1941-56.
    View in: PubMed
    Score: 0.017
  45. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer. 2002 Dec; 35(4):340-52.
    View in: PubMed
    Score: 0.017
  46. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002 Oct; 110(7):923-32.
    View in: PubMed
    Score: 0.017
  47. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
    View in: PubMed
    Score: 0.017
  48. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
    View in: PubMed
    Score: 0.015
  49. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999 Feb; 41(2):257-67.
    View in: PubMed
    Score: 0.013
  50. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997 Jan 07; 94(1):237-41.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.